Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up
Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own
